Anti-Androgen Monotherapy Archives

Optimal treatment of older patients with recurrent prostate cancer now involves more of a decision process than in the past, say the authors of a review article in the journal Drugs & Aging.

Web Exclusives

Some breast cancers may respond to anti-androgen drug

By

Delicia Honen Yard

December 20, 2012

Newly approved for prostate cancer, enzalutamide may be useful as a therapeutic agent in breast cancer that evades other treatments.

Web Exclusives

Annual report highlights 2012 cancer advances

By

Delicia Honen Yard

December 17, 2012

The American Society of Clinical Oncology has released a nearly 100-page report detailing the year’s most significant developments in cancer.

Web Exclusives

Bladder cancer may respond to antiandrogen therapy

By

Delicia Honen Yard

October 17, 2012

A protein that confers a worse prognosis in bladder cancer when present in high levels may respond to antiandrogen therapy used in prostate cancer.

Web Exclusives

New drugs change treatment landscape for advanced prostate cancer

By

Delicia Honen Yard

March 5, 2012

Several newly approved drugs plus more in the pipeline present the real possibility of prolonging survival in men with advanced prostate cancer.

Prostate Cancer

Prostate cancer treatments and heart disease risk

By

Tom Moberly

January 26, 2010

Hormone therapy for prostate cancer increases men’s risk of dying from heart disease, but the additional risk varies almost sevenfold for different treatments, a King’s College London study has found.